Top Parkinson’s Experts Join Inhibikase Therapeutics Scientific Advisory Board

Mary Chapman avatar

by Mary Chapman |

Share this article:

Share article via email
Biogen, Pfzier

To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB).

The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline includes prospective therapies developed from its proprietary Re-engineering Approach with Metabolism Preserved (RAMP) drug innovation engine, which uses validated kinase inhibitors that have an established safety profile and re-enginer them with specific criteria to some of better effectiveness at lower doses.

Its lead product candidate, lkT-148009, is a first-in-class small-molecule oral medication that targets an underlying biological mechanism believed to lead to Parkinson’s disease, with the goal of restricting disease progression. Specifically, the compound aims to block activation of Abl kinase — a regulator that plays a central role in Parkinson’s disease progression — to prevent or reverse the loss of dopamine-secreting neurons in the brain and gastrointestinal tract by restoring neuroprotective mechanisms.

Abl kinases are thought to play a critical role in monitoring insults to neurons inside and outside the brain, and regulating biological pathways responsible for protecting neurons from dying. 

Last month, the company filed two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) to advance lkT-48009 into the clinic, including one using standard measures as a primary readout of treatment benefit. The second one will use novel diagnostic tools and natural history data to evaluate lkT-48009.

Inhibikase expects first-in-human studies to start in the next quarter.

Meanwhile, the company’s newly appointed SAB members are:

”We are pleased to welcome Dr. Olanow, Dr. Kieburtz and Dr. Hauser to our scientific board,” Milton Werner, PhD,  president and CEO of Inhibikase, said in a press release. “As Inhibikase continues to learn as a company, we believe their clinical development, treatment expertise and successful track record will be a critical asset as we continue to explore our approach to potentially both halt and reverse Parkinson’s disease.”